OraSure Technologies Azioni (NASDAQ: OSUR)

OraSure Technologies (NASDAQ:OSUR) Azioni

OraSure Technologies

OraSure Technologies Inc is a medical devices company that develops, manufactures, and distributes oral fluid diagnostic and collection devices. Its reportable segments are diagnostics and molecular solutions. The diagnostics segment produces rapid oral diagnostic tests and specimen collection devices for infectious diseases such as HIV and HCV. The molecular solutions segment specializes in kits used to collect, stabilize, and transport genetic material samples for molecular testing of both hereditary diseases and infectious diseases, such as COVID-19. The company gets majority of its sales from the molecular solutions business, derived mainly from customers in the United States.

News

Offerings

OSUR

Orasure Technologies Files For Mixed Shelf Of Up To $300M

Evercore ISI Group analyst Vijay Kumar maintains OraSure Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OSUR#NASDAQ">OSUR</a>) with a In-Line and maintains $3 price target.

Price Target

Analyst Ratings

Evercore ISI Group Maintains In-Line on OraSure Technologies, Maintains $3 Price Target

Trading Ideas

Watching OraSure Technologies; Evercore ISI Says OSUR Has Previously Disclosed That REGN Is Already An Existing Customer, Which Should Bode Well For A Continued Relationship Between OSUR And 23&Me; We Estimate That 23andMe Was A ~$13M Customer For OSUR In 2024

OraSure Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OSUR#NASDAQ">OSUR</a>) sees Q2 sales of $28.500 million-$32.500 million vs $32.96 million analyst estimate.

Guidance

OraSure Technologies Sees Q2 Sales $28.500M-$32.500M vs $32.96M Est

OraSure Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OSUR#NASDAQ">OSUR</a>) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.20) by 10 percent. This is a 550 percent decrease over earnings of $0.04 per share from the same period last year. The company reported quarterly sales of $29.93 million which beat the analyst consensus estimate of $29.18 million by 2.57 percent. This is a 44.71 percent decrease over sales of $54.13 million the same period last year.

Earnings

Earnings Beats

OraSure Technologies Q1 Adj. EPS $(0.18) Beats $(0.20) Estimate, Sales $29.93M Beat $29.18M Estimate

ACAD

ACDC

ACRE

ACVA

ADMA

ADNT

ADTN

AIRG

ALNT

ALTG

ALTO

ALVO

AMPH

AMPL

AMRK

AMRN

AOSL

APLS

ARIS

ARMN

ASLE

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

AVDX

AXON

AXTA

AZTA

BAND

BBDO

BBGI

BBSI

BGSF

Brighthouse Financial, Inc. - Common Stock

BLBD

BLMN

BLZE

BMBL

BRKR

BROS

BTMD

BXSL

BYND

CAPL

CCSI

CDLX

CENT

CENTA

CENX

CEVA

CIVI

CMTG

CNDT

COHR

Core Scientific, Inc. - Class A Common Stock

CORZ

CPRX

CRNC

CRNT

CSGS

CSTE

CTVA

CVNA

CYRX

Earnings Scheduled For May 7, 2025

WIIM

OraSure Technologies shares are trading higher after the company announced its board authorized a $40 million stock repurchase program.

Buybacks

OraSure Board Authorizes $40M Stock Repurchase Program

OraSure Technologies shares are trading lower after the company issued Q1 revenue guidance below estimates.

OraSure Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OSUR#NASDAQ">OSUR</a>) sees Q1 sales of $27.500 million-$31.500 million vs $32.38 million analyst estimate.

OraSure Technologies Sees Q1 Sales $27.500M-$31.500M vs $32.38M Est

OraSure Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OSUR#NASDAQ">OSUR</a>) reported quarterly losses of $(0.06) per share which met the analyst consensus estimate. This is a 133.33 percent decrease over earnings of $0.18 per share from the same period last year. The company reported quarterly sales of $37.45 million which beat the analyst consensus estimate of $36.72 million by 1.98 percent. This is a 50.65 percent decrease over sales of $75.88 million the same period last year.

OraSure Technologies Q4 Adj $(0.06), Inline, Sales $37.45M Beat $36.72M Estimate

AHCO

ALLT

ARQT

AXGN

BASE

BGFV

BTDR

BWIN

CART

CAVA

CBLL

CCCS

CECO

CGBD

CHRD

CIFR

CPNG

CPSS

DAWN

DNUT

DOCN

DRVN

ELAN

EXLS

FIHL

FLYW

FSLR

FULC

GPOR

HRMY

HSIC

HURN

HYLN

IART

ICCC

IGIC

IMOS

INGN

INTU

INVX

IPAR

ITRI

IVAC

JACK

JAZZ

KEYS

KNSA

LCID

LGIH

LIVN

LMND

LXFR

MASI

MATX

MFIC

MIDD

MMSI

MPLN

MRVI

NOVT

NXRT

Earnings Scheduled For February 25, 2025

The change expands the approved age range to include individuals 14 years of age and older for the OraQuick&#xAE; HIV Self-Test. Previously the test was approved for use in those 17 and older.
According to the most recent data available from the Centers for Disease Control &amp; Prevention, it is estimated that 19 percent of new HIV diagnoses in the United States were among young people aged 13 to 24, and only 6 percent of high school students have ever been tested for HIV. Almost half of young people with HIV do not know that they have it.

OraQuick HIV Self-Test Gains Approval For Adolescents, Expanding Access To HIV Testing For Ages 14 And Up

OraSure Technologies, Inc. ("OTI") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OSUR#NASDAQ">OSUR</a>), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced the acquisition of Sherlock Biosciences, Inc., a global health company bringing next-generation diagnostics to consumers and healthcare providers.
This acquisition expands OraSure's innovation pipeline with the addition of Sherlock's molecular diagnostics platform, which is able to provide rapid results with strong sensitivity and specificity in a disposable format that is well-suited for over-the-counter usage. Sherlock's first molecular self-test is for Chlamydia Trachomatis (CT) and Neisseria Gonorrhoeae (NG) which will expand OraSure's portfolio of rapid diagnostics for sexually transmitted infections (STIs), subject to regulatory approvals. Test results are expected to be provided in under 30 minutes by analyzing DNA and RNA from self-collected swabs using isothermal amplification. In addition, Sherlock has been developing a pipeline of other molecular tests, along with several next-generation technology platforms, including Ambient Temperature Amplification and CRISPR-based technologies that have the potential to further reduce costs and improve performance of its platforms.

OraSure Technologies Acquires Sherlock Biosciences; No Financial Terms Disclosed

OraSure Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OSUR#NASDAQ">OSUR</a>), a leader in point-of-care and home diagnostic tests and sample management solutions, today announced that it received an award through the Rapid Response Partnership Vehicle (RRPV) for the development of a Marburg Virus Disease (MVD) rapid antigen test. The RRPV is a Consortium funded by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS).
The initial contract award, valued at approximately $7.5 million over multiple years in the base period with potential value up to $11 million, funds the development to achieve U.S. Food and Drug Administration (FDA) 510(k) clearance of a single-use lateral flow immunoassay intended for the qualitative detection of antigens from viruses within the Marburg virus genus. We expect that the proposed test will be intended for use with specimens from individuals with epidemiological risk factors who have signs or symptoms of MVD or from recently deceased individuals with epidemiological risk factors who are suspected to have died of MVD.

OraSure Secures $7.5M Contract With $11M Potential for Marburg Virus Rapid Test Development

OraSure Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OSUR#NASDAQ">OSUR</a>) reported quarterly losses of $(0.01) per share which beat the analyst consensus estimate of $(0.08) by 87.5 percent. The company reported quarterly sales of $39.915 million which beat the analyst consensus estimate of $39.019 million by 2.30 percent. This is a 55.25 percent decrease over sales of $89.187 million the same period last year.

OraSure Technologies Q3 2024 Adj. EPS $(0.01) Beats $(0.08) Estimate, Sales $39.915M Beat $39.019M Estimate

Disclosed in the latest SEC filing, a significant insider purchase on September 10, involves John Kenny, Board Member at OraSure Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OSUR#NASDAQ">OSUR</a>).
What Happened: In a recent Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001116463/000106299324016411//Archives/edgar/data/1116463/000106299324016411/0001062993-24-016411-index.htm">U.S. Securities and Exchange Commission</a> on Tuesday, Kenny increased their investment in OraSure Technologies by purchasing 23,256 shares through open-market transactions, signaling confidence in the company's potential. The total transaction value is $100,000.
Monitoring the market, OraSure Technologies's shares up by 0.48% at $4.23 during Wednesday's morning.
<h3>About OraSure Technologies</h3>
OraSure Technologies Inc is a medical devices company that develops, manufactures, and distributes oral fluid diagnostic and collection devices. Its reportable segments are diagnostics and molecular solutions. The diagnostics segment produces rapid oral diagnostic tests and specimen collection devices for infectious diseases such as HIV and HCV. The molecular solutions segment specializes in kits used to collect, stabilize, and transport genetic material samples for molecular testing of both hereditary diseases and infectious diseases, such as COVID-19. The company gets majority of its sales from the molecular solutions business, derived mainly from customers in the United States.
<h3>OraSure Technologies: Delving into Financials</h3>
Negative Revenue Trend: Examining OraSure Technologies's financials over 3 months reveals challenges. As of 30 June, 2024, the company experienced a decline of approximately -36.41% in revenue growth, reflecting a decrease in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Profitability Metrics:
<ul>
<li>
Gross Margin: The company issues a cost efficiency warning with a low gross margin of 45.44%, indicating potential difficulties in maintaining profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): OraSure Technologies's EPS reflects a decline, falling below the industry average with a current EPS of -0.01.
</li>
</ul>
Debt Management: OraSure Technologies's debt-to-equity ratio is below the industry average at 0.03, reflecting a lower dependency on debt financing and a more conservative financial approach.
Valuation Analysis:
<ul>
<li>
Price to Earnings (P/E) Ratio: The Price to Earnings ratio of 11.69 is lower than the industry average, indicating potential undervaluation for the stock.
</li>
<li>
Price to Sales (P/S) Ratio: With a P/S ratio of 1.15 below industry standards, the stock shows potential undervaluation, making it an appealing investment option for those focusing on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): The company's EV/EBITDA ratio 1.91 is below the industry average, indicating that it may be relatively undervalued compared to peers.
</li>
</ul>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Navigating the Impact of Insider Transactions on Investments</h3>
Insightful as they may be, insider transactions should be considered alongside a thorough examination of other investment criteria.
Within the legal framework, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities as per Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are mandated to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
The initiation of a new purchase by a company insider serves as a strong indication that they expect the stock to rise.
However, insider sells may not always signal a bearish view and can be influenced by various factors.
<h3>Navigating the World of Insider Transaction Codes</h3>
When it comes to transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> tend to focus on those in the open market, detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S indicates a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001116463">Check Out The Full List Of OraSure Technologies's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

Smart Money Move: John Kenny Grabs $100K Worth Of OraSure Technologies Stock

OraSure Technologies shares are trading lower after the company issued Q3 revenue guidance below estimates.

Evercore ISI Group analyst Vijay Kumar maintains OraSure Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OSUR#NASDAQ">OSUR</a>) with a In-Line and raises the price target from $4.5 to $5.

Evercore ISI Group Maintains In-Line on OraSure Technologies, Raises Price Target to $5

Financial Guidance
The Company is guiding to Q3 2024 revenues of $37 to $41 million, which includes Core revenues of $36 to $39 million and InteliSwab&#xAE; revenues of $1 to $2 million.

OraSure Sees Q3 2024 Revenue $37M-$41M Vs $52.13M Estimate

Press Releases

OraSure Technologies Acquires Sherlock Biosciences

Health Care

OraQuick® HIV Self-Test Now Approved for Use in Adolescents

CORRECTION - OraQuick® HIV Self-Test Now Approved for Use in Adolescents

OraSure to Present at the J.P Morgan Healthcare Conference

OraSure to Announce Fourth Quarter 2024 Financial Results and Host Earnings Call on February 25th

OraSure Reports Fourth Quarter 2024 Financial Results

OraSure Announces $40 Million Stock Repurchase Program

OraSure to Announce First Quarter 2025 Financial Results and Host Earnings Call on May 7th

OraSure Announces First Quarter 2025 Financial Results

General

Targeted Genomics Announces Commercial Collaboration with OraSure Technologies for Direct to Consumer (DTC) Celiac Genetic Testing

Comments

OraSure Technologies

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO